Abstract:Two thirds of breast cancers express estrogen receptors (ER). ER alpha (ERα) mediates breast cancer cell proliferation, and expression of ERα is the standard choice to indicate adjuvant endocrine therapy. ERbeta (ERβ) inhibits growth in vitro; its effects in vivo have been incompletely investigated and its role in breast cancer and potential as alternative target in endocrine therapy needs further study. In this work, mammary epithelial (EpH4 and HC11) and breast cancer (MC4-L2) cells with endogenous ERα and ERβ expression and T47-D human breast cancer cells with recombinant ERβ (T47-DERβ) were used to explore effects exerted in vitro and in vivo by the ERβ agonists 2,3-bis (4–hydroxy–phenyl)-propionitrile (DPN) and 7-bromo-2-(4–hydroxyphenyl)-1,3-benzoxazol-5-ol (WAY). In vivo, ERβ agonists induced mammary gland hyperplasia and MC4-L2 tumour growth to a similar extent as the ERα agonist 4,4′,4′′-(4-propyl-(1H)-pyrazole-1,3,5-triyl) trisphenol (PPT) or 17β-estradiol (E2) and correlated with higher number of mitotic and lower number of apoptotic features. In vitro, in MC4-L2, EpH4 or HC11 cells incubated under basal conditions, ERβ agonists induced apoptosis measured as upregulation of p53 and apoptosis-inducible factor protein levels and increased caspase 3 activity, whereas PPT and E2 stimulated proliferation. However, when extracellular signal-regulated kinase 1 and 2 (ERK ½) were activated by co-incubation with basement membrane extract or epidermal growth factor, induction of apoptosis by ERβ agonists was repressed and DPN induced proliferation in a similar way as E2 or PPT. In a context of active ERK ½, phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/RAC-alpha serine/threonine-protein kinase (AKT) signalling was necessary to allow proliferation stimulated by ER agonists. Inhibition of MEK ½ with UO126 completely restored ERβ growth-inhibitory effects, whereas inhibition of PI3K by LY294002 inhibited ERβ-induced proliferation. These results show that the cellular context modulates ERβ growth-inhibitory effects and should be taken into consideration upon assessment of ERβ as target for endocrine treatment.

Activation of peroxisome proliferator-activated receptor-β/δ (PPAR-β/δ) inhibits human breast cancer cell line tumorigenicity

Overexpression of ERα Inhibits Proliferation and Invasion of MKN28 Gastric Cancer Cells by Suppressing Β-Catenin

PPARγ Ligands Inhibit Cholangiocarcinoma Cell Growth Through P53-Dependent GADD45 and P21waf1/cip1 Pathway

Peroxisome Proliferator-Activated Receptor Γ Ligands Induce Cell Cycle Arrest and Apoptosis in Human Renal Carcinoma Cell Lines

PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway.

Toll-Like Receptor 9 Agonist Inhibits Er Alpha-Mediated Transactivation by Activating Nf-Kappa B in Breast Cancer Cell Lines

Selective activation of PPARgamma in breast, colon, and lung cancer cell lines

Ppar Gamma And Wnt/Beta-Catenin Pathway In Human Breast Cancer: Expression Pattern, Molecular Interaction And Clinical/Prognostic Correlations

Differential Effects of Estrogen Receptor Alpha and Beta on Endogenous Ligands of Peroxisome Proliferator-Activated Receptor Gamma in Papillary Thyroid Cancer

Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells

Peroxisome proliferator-activated receptor-γ activation inhibits hepatocellular carcinoma cell invasion by upregulating plasminogen activator inhibitor-1.

Recruited Metastasis Suppressor NM23-H2 Attenuates Expression and Activity of Peroxisome Proliferator-Activated Receptor Δ (pparδ) in Human Cholangiocarcinoma.

Regulation of drug resistance by human pregnane X receptor in breast cancer.

Peroxisome Proliferator-Activated Receptor Γ Ligands Induce Apoptosis of Renal Cell Carcinoma

PTHrP expression in human MDA-MB-231 breast cancer cells is critical for tumor growth and survival and osteoblast inhibition

Effects of PolyphyllinⅡ in Growth Inhibition of Human Breast Cancer Cells

PPARγ2 Functions As a Tumor Suppressor in a Translational Mouse Model of Human Prostate Cancer

Parthenolide Induces Proliferation Inhibition and Apoptosis of Pancreatic Cancer Cells in Vitro

Function Analysis of Estrogenically Regulated Protein Tyrosine Phosphatase Γ (ptpγ) in Human Breast Cancer Cell Line MCF-7

PPAR-γ ligand promotes the growth of APC-mutated HT-29 human colon cancer cells in vitro and in vivo

Inhibition of Cancer Cell Proliferation by PPARγ is Mediated by a Metabolic Switch That Increases Reactive Oxygen Species Levels.